A total of 20 patients with HER2 positive DCIS received a dose of 1500 mg daily of lapatinib for 4 consecutive weeks prior to surgical resection with radiographic changes evaluated by MRI [21]. The gene discussed is ERBB2; the disease is ductal breast carcinoma in situ.